Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1.
Trials. 2022.
PMID: 35578360
Free PMC article.
Determination of plasma protein binding of dalbavancin.
Turner NA, Xu A, Zaharoff S, Holland TL, Lodise TP.
Turner NA, et al. Among authors: zaharoff s.
J Antimicrob Chemother. 2022 Jun 29;77(7):1899-1902. doi: 10.1093/jac/dkac131.
J Antimicrob Chemother. 2022.
PMID: 35488862
Free PMC article.
Item in Clipboard
The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.
Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG; Antibacterial Resistance Leadership Group.
Chambers HF, et al.
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S279-S287. doi: 10.1093/cid/ciad475.
Clin Infect Dis. 2023.
PMID: 37843121
Item in Clipboard
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, Rouphael N, Evans SR, Fowler VG, Hamasaki T, Patel R, Komarow L, Baum K, Souli M, Schwager N, Bonomo RA, Doi Y; Antibacterial Resistance Leadership Group.
Satlin MJ, et al.
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S305-S313. doi: 10.1093/cid/ciad547.
Clin Infect Dis. 2023.
PMID: 37843118
Item in Clipboard
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
Doernberg SB, Arias CA, Altman DR, Babiker A, Boucher HW, Creech CB, Cosgrove SE, Evans SR, Fowler VG, Fritz SA, Hamasaki T, Kelly BJ, Leal SM, Liu C, Lodise TP, Miller LG, Munita JM, Murray BE, Pettigrew MM, Ruffin F, Scheetz MH, Shopsin B, Tran TT, Turner NA, Williams DJ, Zaharoff S, Holland TL; Antibacterial Resistance Leadership Group.
Doernberg SB, et al. Among authors: zaharoff s.
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S295-S304. doi: 10.1093/cid/ciad565.
Clin Infect Dis. 2023.
PMID: 37843115
Review.
Item in Clipboard
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Wall A, Wiegand K, Chambers HF; Antibacterial Resistance Leadership Group.
Lodise TP, et al. Among authors: zaharoff s.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17.
Antimicrob Agents Chemother. 2022.
PMID: 36394326
Free PMC article.
Clinical Trial.
Item in Clipboard
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.
Lodise TP, O'Donnell JN, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Beresnev T, Wall A, Wiegand K, Serti Chrisos E, Balevic S, Chambers HF; Antibacterial Resistance Leadership Group.
Lodise TP, et al. Among authors: zaharoff s.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093522. doi: 10.1128/aac.00935-22. Epub 2022 Nov 17.
Antimicrob Agents Chemother. 2022.
PMID: 36394316
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite